Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

A drug-eluting spacer for temporary implantation in a knee joint includes a femoral component configured to interface with a femur, a tibial tray component having an upper surface, a lower surface, and a shaft extending from the lower surface, the shaft configured to be positioned axially within a tibia, the lower surface configured to interface with the tibia, and a tibial insert component having an upper surface and a lower surface, the lower surface of the tibial insert component configured to engage the upper surface of the tibial tray component, the upper surface of the tibial insert component configured to receive the femoral component in an articulating manner. The femoral component, the tibial tray component, and the tibial insert component carry joint loads when implanted. The drug-eluting spacer is configured to elute a biologically active agent in an amount effective to treat an infection of the knee joint.

A drug-eluting spacer for temporary implantation in a knee joint includes a femoral component configured to interface with a femur, a tibial tray component having an upper surface, a lower surface, and a shaft extending from the lower surface, the shaft configured to be positioned axially within a tibia, the lower surface configured to interface with the tibia, and a tibial insert component having an upper surface and a lower surface, the lower surface of the tibial insert component configured to engage the upper surface of the tibial tray component, the upper surface of the tibial insert component configured to receive the femoral component in an articulating manner. The femoral component, the tibial tray component, and the tibial insert component carry joint loads when implanted. The drug-eluting spacer is configured to elute a biologically active agent in an amount effective to treat an infection of the knee joint.

Methods of treating a Gram negative bacterial infection comprising a co-administration regimen of an effective amount of fosfomycin together with at least one antimicrobial agent selected from the group consisting of piperacillin-tazobactam, ceftazidime and meropenem to an infected subject. A further method of treating a subject with a bacterial infection that includes infection with a “resistant” mutant subpopulation selected from the group consisting of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, Acinetobacter baumannii and E. coli, the method comprising (a) obtaining a sample from a subject suffering from a bacterial infection; (b) identifying the presence of the “resistant” mutant subpopulation in said sample; and (c) co-administering fosfomycin and at least one antimicrobial agent to the subject, wherein after the co-administration, the bacterial density is effectively reduced and the “resistant” mutant subpopulation is inhibited.

Methods of treating a Gram negative bacterial infection comprising a co-administration regimen of an effective amount of fosfomycin together with at least one antimicrobial agent selected from the group consisting of piperacillin-tazobactam, ceftazidime and meropenem to an infected subject. A further method of treating a subject with a bacterial infection that includes infection with a “resistant” mutant subpopulation selected from the group consisting of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, Acinetobacter baumannii and E. coli, the method comprising (a) obtaining a sample from a subject suffering from a bacterial infection; (b) identifying the presence of the “resistant” mutant subpopulation in said sample; and (c) co-administering fosfomycin and at least one antimicrobial agent to the subject, wherein after the co-administration, the bacterial density is effectively reduced and the “resistant” mutant subpopulation is inhibited.

Methods of treating a Gram negative bacterial infection comprising a co-administration regimen of an effective amount of fosfomycin together with at least one antimicrobial agent selected from the group consisting of piperacillin-tazobactam, ceftazidime and meropenem to an infected subject. A further method of treating a subject with a bacterial infection that includes infection with a “resistant” mutant subpopulation selected from the group consisting of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, Acinetobacter baumannii and E. coli, the method comprising (a) obtaining a sample from a subject suffering from a bacterial infection; (b) identifying the presence of the “resistant” mutant subpopulation in said sample; and (c) co-administering fosfomycin and at least one antimicrobial agent to the subject, wherein after the co-administration, the bacterial density is effectively reduced and the “resistant” mutant subpopulation is inhibited.

The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.

The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.